美国胃肠病学会临床实践更新:肝硬化患者门静脉血栓的管理专家评论
该临床实践更新由美国胃肠病学会(AGA)研究所临床实践更新委员会委托,基于文献综述与专家意见,为肝硬化门静脉血栓(PVT)的评估和管理提供最佳实践建议,涵盖直接口服抗凝药和血管内干预的作用,未进行系统评价,建议不附带正式证据质量或推荐强度评级。
要点
- 代偿期肝硬化无症状患者无需常规筛查门静脉血栓。
- 多普勒超声发现PVT后应行CT或MRI确认诊断并评估恶性、闭塞程度、血栓范围及慢性程度。
- 无肠缺血且近期(<6个月)血栓累及肝内门静脉分支或主干、脾静脉或肠系膜静脉闭塞<50%者可观察并每3个月复查影像。
核心结论
- 该临床实践更新为肝硬化PVT的评估和管理提供11条最佳实践建议,涵盖筛查、诊断、抗凝指征、抗凝药物选择及血管内干预。
- 建议基于文献综述和专家意见,未进行系统评价,不附带正式证据质量或推荐强度评级。
研究设计与样本
- 由美国胃肠病学会(AGA)研究所临床实践更新委员会委托并批准、AGA理事会批准的专家评论,经内部同行评议和《Gastroenterology》标准外部同行评议。
- 建议来自已发表文献综述和专家意见,未进行系统评价,未对证据质量或推荐强度进行正式评级。
主要发现
- 代偿期肝硬化无症状患者无需常规筛查PVT。
- 多普勒超声发现PVT后应行CT或MRI确认诊断、评估恶性、记录管腔闭塞程度、血栓范围和慢性程度。
- 无其他血栓栓塞、实验室异常或提示易栓症家族史时,无需行高凝状态检查。
- 有肠缺血证据的PVT患者需紧急抗凝,并应由包括胃肠病和肝病、介入放射、血液和外科的多学科团队管理。
- 无肠缺血且近期(<6个月)血栓累及肝内门静脉分支或主干、脾静脉或肠系膜静脉闭塞<50%者,可考虑观察并每3个月复查影像直至血栓消退。
关键数值与推荐
- 建议1:代偿期肝硬化无症状患者不需常规筛查PVT。
- 建议2:多普勒超声发现PVT应行CT或MRI确认诊断、评估恶性、记录管腔闭塞程度、血栓范围和慢性程度。
- 建议3:无其他血栓栓塞、实验室异常或提示易栓症家族史时,不需行高凝状态检查。
- 建议4:有肠缺血证据者需紧急抗凝,并应由多学科团队管理。
- 建议5:无肠缺血且近期(<6个月)血栓累及肝内门静脉分支或主干、脾静脉或肠系膜静脉闭塞<50%者,可考虑观察并每3个月复查影像直至血栓消退。
临床怎么用
- 建议6:无肠缺血且近期(<6个月)PVT闭塞>50%或累及门静脉主干或肠系膜血管者,应考虑抗凝;再通获益增加者包括累及超过1个血管床、血栓进展、潜在肝移植候选者和遗传性易栓症患者。
- 建议7:慢性(>6个月)PVT完全闭塞伴侧支形成(海绵样变)者不建议抗凝。
- 建议8:PVT患者如未在接受非选择性β受体阻滞剂预防出血,应行内镜下静脉曲张筛查;避免延迟启动抗凝,因延迟会降低门静脉再通的几率。
- 建议9:维生素K拮抗剂、低分子肝素和直接口服抗凝药均为肝硬化PVT的合理抗凝选择;决策应个体化并参考患者偏好和Child-Turcotte-Pugh分级;直接口服抗凝药可考虑用于代偿期Child-Turcotte-Pugh A级和B级肝硬化,其剂量无需监测国际标准化比值,提供便利。
- 建议10:抗凝治疗中的PVT患者应每3个月行横断面影像评估治疗反应;如血栓消退,应继续抗凝直至移植或非移植患者至少至血栓消退。
局限性
- 未进行系统评价,最佳实践建议不附带正式的证据质量或推荐强度评级。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DESCRIPTION: Portal vein thromboses (PVTs) are common in patients with cirrhosis and are associated with advanced portal hypertension and mortality. The treatment of PVTs remains a clinical challenge due to limited evidence and competing risks of PVT-associated complications vs bleeding risk of anticoagulation. Significant heterogeneity in PVT phenotype based on anatomic, host, and disease characteristics, and an emerging spectrum of therapeutic options further complicate PVT management. This Clinical Practice Update (CPU) aims to provide best practice advice for the evaluation and management of PVT in cirrhosis, including the role of direct oral anticoagulants and endovascular interventions. METHODS: This expert review was commissioned and approved by the American Gastroenterological Association (AGA) Institute CPU Committee and the AGA Governing Board to provide timely guidance on a topic of high clinical importance to the AGA membership, and underwent internal peer review by the CPU Committee and external peer review through standard procedures of Gastroenterology. These Best Practice Advice statements were drawn from a review of the published literature and from expert opinion. Because systematic reviews were not performed, these Best Practice Advice statements do not carry formal ratings regarding the quality of evidence or strength of the presented considerations. Best Practice Advice Statements BEST PRACTICE ADVICE 1: Asymptomatic patients with compensated cirrhosis do not require routine screening for PVT. BEST PRACTICE ADVICE 2: Patients with cirrhosis with PVTs identified on Doppler ultrasound should undergo cross-sectional imaging with computed tomography or magnetic resonance imaging to confirm the diagnosis, evaluate for malignancy, and document the degree of lumen occlusion, clot extent, and chronicity. BEST PRACTICE ADVICE 3: Patients with cirrhosis and PVT do not require a hypercoagulable workup in the absence of additional thromboemboli or laboratory abnormalities or family history suggestive of thrombophilia. BEST PRACTICE ADVICE 4: Patients with cirrhosis and PVT with evidence of intestinal ischemia require urgent anticoagulation to minimize ischemic injury. If available, these patients should be managed by a multidisciplinary team, including gastroenterology and hepatology, interventional radiology, hematology, and surgery. BEST PRACTICE ADVICE 5: Consider observation, with repeat imaging every 3 months until clot regression, in patients with cirrhosis without intestinal ischemia and recent (<6 months) thrombosis involving the intrahepatic portal vein branches or when there is <50% occlusion of the main portal vein, splenic vein, or mesenteric veins. BEST PRACTICE ADVICE 6: Anticoagulation should be considered in patients with cirrhosis without intestinal ischemia who develop recent (<6 months) PVT that is >50% occlusive or involves the main portal vein or mesenteric vessels. Patients who have increased benefit of recanalization include those with involvement of more than 1 vascular bed, those with thrombus progression, potential liver transplantation candidates, and those with inherited thrombophilia. BEST PRACTICE ADVICE 7: Anticoagulation is not advised for patients with cirrhosis with chronic (>6 months) PVT with complete occlusion with collateralization (cavernous transformation). BEST PRACTICE ADVICE 8: Patients with cirrhosis and PVT warrant endoscopic variceal screening if they are not already on nonselective beta-blocker therapy for bleeding prophylaxis. Avoid delays in the initiation of anticoagulation for PVT, as this decreases the odds of portal vein recanalization. BEST PRACTICE ADVICE 9: Vitamin K antagonists, low-molecular-weight heparin, and direct oral anticoagulants are all reasonable anticoagulant options for patients with cirrhosis and PVT. Decision making should be individualized and informed by patient preference and Child-Turcotte-Pugh class. Direct oral anticoagulants may be considered in patients with compensated Child-Turcotte-Pugh class A and Child-Turcotte-Pugh class B cirrhosis and offer convenience as their dosages are independent of international normalized ratio monitoring. BEST PRACTICE ADVICE 10: Patients with cirrhosis on anticoagulation for PVT should have cross-sectional imaging every 3 months to assess response to treatment. If clot regresses, anticoagulation should be continued until transplantation or at least clot resolution in nontransplantation patients. BEST PRACTICE ADVICE 11: Portal vein revascularization with transjugular intrahepatic portosystemic shunting may be considered for selected patients with cirrhosis and PVT who have additional indications for transjugular intrahepatic portosystemic shunting, such as those with refractory ascites or variceal bleeding. Portal vein revascularization with transjugular intrahepatic portosystemic shunting may also be considered for transplantation candidates if recanalization can facilitate the technical feasibility of transplantation.
引用
- Davis JPE, Lim JK, Francis FF, et al. AGA Clinical Practice Update on Management of Portal Vein Thrombosis in Patients With Cirrhosis: Expert Review. Gastroenterology. 2024. PMID: 39708000. doi:10.1053/j.gastro.2024.10.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。